Individuals with mutations in TRIO present with a range of NDD-associated clinical features, including varying degrees of intellectual disability, altered head size, skeletal and facial features, and behavioral abnormalities (Ba et al., 2016; Barbosa et al., 2020; Gazdagh et al., 2023; Pengelly et al., 2016; Bircher et al., 2022; Bonnet et al., 2023; Schultz-Rogers et al., 2020). This evidence concerns the gene TRIO and Neurodevelopmental delay.